Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 147972
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 147162
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-15 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 146353
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 145603
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 145286
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2001-12-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

SYNTHELABO

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 147972
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 147162
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-15 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 146353
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 145603
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2002-01-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 145286
                    [Title] => Sanofi-Synthelabo and Cephalon ink agreement
                    [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.



This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.



                    [DatePublished] => 2001-12-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

Sanofi-Synthelabo and Cephalon ink agreement

January 22, 2002 - 12:00am

Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors. This agreement includes a number of orally active molecules that...

Health And Family

Sanofi-Synthelabo and Cephalon ink agreement

January 15, 2002 - 12:00am

Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors. This agreement includes a number of orally active molecules that...

Health And Family

Sanofi-Synthelabo and Cephalon ink agreement

January 8, 2002 - 12:00am

Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors. This agreement includes a number of orally active molecules that...

Health And Family

Sanofi-Synthelabo and Cephalon ink agreement

January 1, 2002 - 12:00am

Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors. This agreement includes a number of orally active molecules that...

Health And Family

Sanofi-Synthelabo and Cephalon ink agreement

December 29, 2001 - 12:00am

Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors. This agreement includes a number of orally active molecules that...

Health And Family